Evidence map›Paper›PMID 34613879›Full record

ArticleHuman vaccines & immunotherapeutics2021

Lessons learned from COVID-19 vaccination in Indonesia: experiences, challenges, and opportunities.

Bondi Arifin, Titik Anas

Abstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Molecular Dynamics Simulation of Ligands fromJournal of tropical medicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Bondi ArifinMinistry of Finance Republic of Indonesia.ORCID 0000-0002-0487-2573
Titik AnasMinistry of Finance Republic of Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of safe and effective COVID-19 vaccines as well as their delivery to people's arms are the best hope for ending the COVID-19 pandemic. However, the implementation of vaccination varies greatly across countries, with the developing countries lagging behind. This study investigates Indonesia's vaccination experiences, challenges, and acceleration over the course of implementation period. This study provides simulations to estimate the vaccination rate using time-series forecasting machine learning. We use Administrative data and Survey results in our analysis. Our findings suggest limited vaccine availability had caused low-coverage vaccination implementation in the early stage of vaccination implementation period. However, following the increased availability of vaccine, the vaccination rate accelerates up to 600% times. The government of Indonesia utilized strategic public places, public and private offices, and engaging private sectors in the phase two implementation to accelerate the vaccination implementation. Indonesia might reach 63.1 million individuals vaccinated at the end of March 2022, or 35% of the targeted population with up to April 2021 vaccination rate. To accelerate, government introduced a number of new strategies including door-to-door persuasion through neighborhood association (RT), educating individuals, and providing transportation from their home to the vaccination facility. We expect new strategies could further improve vaccination speed by around 1.4 million to 3.5 million individuals per day.

Indexed as

COVID-19COVID-19 VaccinesHumansIndonesiaPandemicsSARS-CoV-2VaccinationCOVID-19 VaccinesCOVID-19vaccination accelerationvaccines

Identifiers

PMID34613879
PMCPMC8828161

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.